1 312-422-1111


BioVie Receives $3.2 Million Equity Investment

On July 3, 2018, BioVie Inc. (OTCQB: BIVI), an iBIO PROPEL company developing innovative drug therapies for liver disease, executed an agreement with Acuitas Group Holdings, LLC (“Acuitas”) and certain other investors to purchase $3.2 million of the Company’s Series A Preferred Stock

Read more

The iBIO Institute Honors Life Sciences Educators, Innovators and Entrepreneurs at the 12th Annual iCON Awards

This evening, the iBIO Institute hosted the twelfth annual iCON awards last night at The Chicago Botanic Garden.

Read more